Focus: Integrated Biosciences is a synthetic biology company leveraging stressed-cell targeting technology to discover drugs across immunology, oncology, neurology, respiratory, and infectious disease. The company operates as a pre-revenue or early-stage biotech with minimal commercial scale.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
High-risk, high-science opportunity best suited for researchers willing to tolerate instability for access to novel platform technology.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Established diagnostic radiopharmaceutical with approaching patent/exclusivity cliff; limited relevance to company's core synthetic biology strategy.
Help build intelligence for Integrated Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Integrated Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent large layoff combined with minimal current hiring indicates high near-term instability; job security is low.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo